Last updated on April 16, 2014 at 12:15 EDT

Debiopharm Group(TM) Presents the ‘Debiopharm Group(TM) Life Sciences Award 2011′ and two ‘Junior Debiopharm Group(TM) Awards 2011′ at the ISREC 2011 Life Sciences Symposium

September 8, 2011

LAUSANNE, Switzerland, September 8, 2011 /PRNewswire/ –

Debiopharm Group(TM) (Debiopharm), a Swiss-based global
biopharmaceutical group with a focus on drug development and companion
diagnostics, will present tomorrow the ‘Debiopharm Group Life Sciences Award
2011′ to Professor Stefano Piccolo as well as two inaugural ‘Junior
Debiopharm Group Life Sciences Awards 2011′ to Professor Etienne Meylan and
Doctor Volker Busskamp. The award ceremony will take place at the EPFL
(Ecole polytechnique federale de Lausanne) during the ISREC (Swiss Institute
for Experimental Cancer Research) 2011 Life Sciences Symposium entitled
‘Hallmarks and horizons of cancer’.

The ‘Debiopharm Group Life Sciences Award 2011′ is granted to Professor
Stefano Piccolo from the University of Padua, Italy. He has made extensive
contributions to the field of cancer, in particular in dissecting the role
of a protein secreted by cells called “transforming growth factor beta
(TGFb)”, and the relation of TGFb to intracellular signalling pathways
involved in cancer initiation and progression. Professor Piccolo is now
working on the role of small RNAs called microRNAs or miRNAs in controlling
overall cell signalling. The award amounts to CHF 50’000.- of which CHF
40’000.- are made available to the awardee’s institute, whilst CHF 10’000.-
are for personal use.

This year, Debiopharm decided to launch the inaugural ‘Junior Debiopharm
Group Life Sciences Awards’. Professor Etienne Meylan from the EPFL and
Doctor Volker Busskamp from the Basel-based Friedrich Miescher Institute for
Biomedical Research (FMI), are the recipients of the ‘Junior Debiopharm
Group Life Sciences Awards’. Each award amounts to CHF 25’000.- of which CHF
20’000.- are made available to the awardees’ respective institutes, whilst
CHF 5’000.- are for personal use. The junior awards are destined to young
researchers in Switzerland, in the field of cellular and molecular biology.
They are ideally at the stage of late postdoctoral studies or launching an
independent research group. The selection criteria are based on excellence
in previous work and originality of future projects.

Professor Meylan has just been appointed tenure-track Professor at the
EPFL, following his postdoctoral work in the laboratory of Professor Tyler
Jacks at MIT. His laboratory at the EPFL focuses on developing mouse models
of lung cancer to test new promising anti-cancer compounds.

Doctor Busskamp recently completed a spectacular Ph.D. thesis in applied
neuroscience at the FMI (Dr. Botond Roska’s laboratory). During his Ph.D.,
he developed and validated a new type of therapy to repair blind retinas in

“Today’s nominees all provided high quality and innovative work,
allowing the jury to reach a unanimous decision,” said Rolland-Yves
Mauvernay, President and founder of Debiopharm Group(TM). “We are happy to
recognise and reward these young scientists for their accomplishments. We
wish them all the best and hope their research will lead to major
discoveries in the medical field in the years to come.”

About Debiopharm Group(TM)

Debiopharm Group(TM) (Debiopharm) is a Swiss-based global
biopharmaceutical group of companies with a focus on the development of
prescription drugs that target unmet medical needs. The group in-licenses,
develops and/or co-develops promising biological and small molecule drug
candidates having reached clinical development phases I, II or III, as well
as earlier stage candidates. It develops its products for global
registration and maximum commercial potential. The products are out-licensed
to pharmaceutical partners for sales and marketing. Debiopharm is also
active in the field of companion diagnostics with a view to progressing in
the area of personalised medicine. Debiopharm independently funds the
worldwide development of all of its products while providing expertise in
pre-clinical and clinical trials, manufacturing, drug delivery and
formulation, and regulatory affairs.

For more information on Debiopharm Group(TM), please visit:


        Debiopharm S.A. Contact
        Maurice Wagner
        Director Corporate Affairs & Communication
        Tel.: +41-(0)21-321-01-11
        Fax: +41-(0)21-321-01-69

        Additional Media Contacts
        In London
        Brian Hudspith
        Tel: +44-(0)20-7379-5151

        In New York
        Russo Partners, LLC
        Lena Evans
        Account Executive
        Tel:  +1-212-845-4262
        Fax: +1-212-845-4260

SOURCE The Debiopharm Group

Source: PR Newswire